# Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer (PROSTIRNA)

> **NCT02866916** · PHASE1 · WITHDRAWN · sponsor: **Institut Claudius Regaud**

## Conditions studied

- Prostatic Cancer, Castration-Resistant

## Interventions

- **DRUG:** SXL01

## Key facts

- **NCT ID:** NCT02866916
- **Lead sponsor:** Institut Claudius Regaud
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-09
- **Primary completion:** 2020-06
- **Final completion:** 2020-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study cancelled
- **Last updated:** 2021-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02866916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02866916, "Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer (PROSTIRNA)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02866916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*